Roche's (RHHBY) phase III study evaluating inavolisib in combination with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation achieves its primary goal.
– Overall response rate of 42% and median progression-free survival of 11.1 months in heavily pre-treated patients (after 11 months median follow-up time and based on 48% of events) demonstrates the potential of vepdegestrant in combination with palbociclib (IBRANCE®) – – Tolerability generally consistent with the profile of palbociclib and what has been observed in other clinical trials of vepdegestrant– – Pending additional data and agreement with regulatory authorities, Arvinas and Pfizer pla
In this article, we discuss 12 best healthcare dividend stocks to buy now. You can skip our detailed analysis of the healthcare sector and the past performance of dividend stocks, and go directly to read 5 Best Healthcare Dividend Stocks To Buy Now. Over the span of almost four years, the COVID-19 pandemic brought about […]